JP2020196718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020196718A5 JP2020196718A5 JP2020126483A JP2020126483A JP2020196718A5 JP 2020196718 A5 JP2020196718 A5 JP 2020196718A5 JP 2020126483 A JP2020126483 A JP 2020126483A JP 2020126483 A JP2020126483 A JP 2020126483A JP 2020196718 A5 JP2020196718 A5 JP 2020196718A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- weight
- ocular
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 53
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims 11
- 229920000153 Povidone-iodine Polymers 0.000 claims 11
- 229960001621 povidone-iodine Drugs 0.000 claims 11
- 150000003431 steroids Chemical class 0.000 claims 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 3
- 230000000845 anti-microbial effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000006184 cosolvent Substances 0.000 claims 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000000813 microbial effect Effects 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229950000812 dexamethasone palmitate Drugs 0.000 claims 2
- 239000003589 local anesthetic agent Substances 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 2
- 235000011152 sodium sulphate Nutrition 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 241000224489 Amoeba Species 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010984 Corneal abrasion Diseases 0.000 claims 1
- 208000028006 Corneal injury Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- 229920002057 Pluronic® P 103 Polymers 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 229940067107 phenylethyl alcohol Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229960002372 tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
- 229940033663 thimerosal Drugs 0.000 claims 1
Claims (34)
- 眼の少なくとも一つの組織の微生物感染または障害の処置および/または予防に有効な、眼への局所投与に適する眼用組成物であって、
(a)0.01重量%〜10重量%の濃度のポビドンヨード、および
(b)デキサメタゾンパルミテートであるステロイド
を含む、眼用組成物。 - 前記ポビドンヨードが、0.1重量%〜2.5重量%である、請求項1に記載の眼用組成物。
- 前記ポビドンヨードが、0.5重量%〜2重量%である、請求項1に記載の眼用組成物。
- 前記ポビドンヨードおよび前記ステロイドの全重量が、前記組成物中の0.1重量%〜4.5重量%である、請求項1〜3のいずれか1項に記載の眼用組成物。
- 前記ステロイドが、0.01重量%〜10重量%の濃度である、請求項1〜4のいずれか1項に記載の眼用組成物。
- 前記ステロイドが、0.05重量%〜2重量%の濃度である、請求項1〜5のいずれか1項に記載の眼用組成物。
- 前記組成物が、痛みを軽減する局所麻酔薬を更に含む、請求項1に記載の眼用組成物。
- 前記局所麻酔薬が、プロパラカイン、リドカイン、テトラカインおよびそれらの組合せから成る群より選択される、請求項7に記載の眼用組成物。
- 前記組成物が、眼の前記組織中へのポビドンヨードの浸透を促進する浸透促進剤を更に含む、請求項1に記載の眼用組成物。
- 前記組成物が、抗微生物性保存剤を更に含む、請求項1〜9のいずれか1項に記載の眼用組成物。
- 前記抗微生物性保存剤が、塩化ベンザルコニウム、チメロサール、クロロブタノール、メチルパラベン、プロピルパラベン、フェニルエチルアルコール、EDTA、ソルビン酸、ポリクオタニウム−1およびそれらの組合せから成る群より選択される、請求項10に記載の眼用組成物。
- 前記抗微生物性保存剤が、前記組成物中の0.001重量%〜1.0重量%の濃度である、請求項10または11に記載の眼用組成物。
- 前記組成物が、共溶媒/界面活性剤を更に含む、請求項1〜12のいずれか1項に記載の眼用組成物。
- 前記共溶媒/界面活性剤が、ポリオキシエチレン(20)ソルビタンモノラウレート、ポリオキシエチレン(20)ソルビタンモノステアレート、ポリオキシエチレン(20)ソルビタンモノオレエート、Pluronic(登録商標)F−68、Pluronic(登録商標)F−84、Pluronic(登録商標)P−103、シクロデキストリン、チロキサポールおよびそれらの組合せから成る群より選択される、請求項13に記載の眼用組成物。
- 前記共溶媒/界面活性剤が、前記組成物中の0.01重量%〜2重量%の濃度である、請求項13または14に記載の眼用組成物。
- 前記組成物が、粘度上昇剤を更に含む、請求項1〜15のいずれか1項に記載の眼用組成物。
- 前記粘度上昇剤が、ポリビニルアルコール、ポリビニルピロリドン、メチルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシエチルセルロース、カルボキシメチルセルロース、ヒドロキシプロピルセルロースおよびそれらの組合せから成る群より選択される、請求項16に記載の眼用組成物。
- 前記粘度上昇剤が、前記組成物中の0.01重量%〜2重量%の濃度である、請求項16または17に記載の眼用組成物。
- 前記組成物が、溶液、懸濁液、エマルジョン、軟膏、クリーム、ゲルまたは制御放出/徐放性ビヒクルの形態である、請求項1〜18のいずれか1項に記載の眼用組成物。
- 0.5%〜2%(w/w)のポビドンヨード;
0.05%〜2%(w/w)のステロイド;
0.005%〜0.02%(w/w)のEDTA;
0.01%〜0.5%(w/w)の塩化ナトリウム;
0.02%〜0.1%(w/w)のチロキサポール;
0.5%〜2%(w/w)の硫酸ナトリウム;および
0.1%〜0.5%(w/w)のヒドロキシエチルセルロース
を含む、請求項1に記載の眼用組成物。 - 1.0%(w/w)のポビドンヨード;
0.1%(w/w)のステロイド;
0.01%(w/w)のEDTA;
0.3%(w/w)の塩化ナトリウム塩;
0.05%(w/w)のチロキサポール;
1.2%(w/w)の硫酸ナトリウム;および
0.25%(w/w)のヒドロキシエチルセルロース
を含む、請求項1に記載の眼用組成物。 - 前記組成物が、照明環境中において3ヶ月間後に、それのポビドンヨードの90%およびそれのステロイドの90%を保持する、請求項1〜21のいずれか1項に記載の眼用組成物。
- 前記組成物が、照明環境中において1年間後に、それのポビドンヨードの90%およびそれのステロイドの90%を保持する、請求項1〜22のいずれか1項に記載の眼用組成物。
- 前記組成物が、水溶液である、請求項1〜23のいずれか1項に記載の眼用組成物。
- 以下のものからなる群から選択される少なくとも一つを治療するための眼用組成物であって:
a)眼の少なくとも一つの組織の微生物感染、
b)結膜炎、及び
c)角膜剥離または眼科手術後の眼の少なくとも一つの組織の微生物感染、
一以上の投与で眼に投与され、眼への局所投与に適しており、
0.01重量%〜10重量%の濃度のポビドンヨードとデキサメタゾンパルミテートであるステロイドとの混合物を含む、眼用組成物。 - 前記微生物が、細菌、ウイルス、真菌またはアメーバである、請求項25に記載の組成物。
- 前記細菌が、ミコバクテリアである、請求項26に記載の組成物。
- 前記ポビドンヨードおよび前記ステロイドの合計が、0.001mg/投与量〜5mg/投与量である、請求項25〜27のいずれか1項に記載の組成物。
- 各々の投与量が、10マイクロリットル〜200マイクロリットルである、請求項25〜28のいずれか1項に記載の組成物。
- 各々の投与量が、50マイクロリットル〜80マイクロリットルである、請求項25〜29のいずれか1項に記載の組成物。
- 前記投与が、前記組成物を前記眼に、1日1回〜4回投与することを含む、請求項25〜30のいずれか1項に記載の組成物。
- 前記投与が、前記組成物を前記眼に、1日1回〜24回投与することを含む、請求項25〜30のいずれか1項に記載の組成物。
- 前記投与の前に、組成物を少なくとも1ヶ月間、少なくとも3ヶ月間、少なくとも6ヶ月間または少なくとも1年間貯蔵される、請求項25〜32のいずれか1項に記載の組成物。
- 前記貯蔵が、照明環境におけるものである、請求項33に記載の組成物。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78262906P | 2006-03-14 | 2006-03-14 | |
US60/782,629 | 2006-03-14 | ||
US84831506P | 2006-09-29 | 2006-09-29 | |
US60/848,315 | 2006-09-29 | ||
US11/636,293 | 2006-12-07 | ||
US11/636,293 US7767217B2 (en) | 2006-03-14 | 2006-12-07 | Ophthalmic compositions comprising povidone-iodine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019006930A Division JP6817346B2 (ja) | 2006-03-14 | 2019-01-18 | ポビドンヨードを含む眼用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020196718A JP2020196718A (ja) | 2020-12-10 |
JP2020196718A5 true JP2020196718A5 (ja) | 2021-01-28 |
Family
ID=38509994
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009500393A Active JP5415935B2 (ja) | 2006-03-14 | 2007-03-09 | ポビドンヨードを含む眼用組成物 |
JP2013034815A Active JP5709279B2 (ja) | 2006-03-14 | 2013-02-25 | ポビドンヨードを含む眼用組成物 |
JP2015021037A Active JP5997303B2 (ja) | 2006-03-14 | 2015-02-05 | ポビドンヨードを含む眼用組成物 |
JP2016134980A Active JP6389487B2 (ja) | 2006-03-14 | 2016-07-07 | ポビドンヨードを含む眼用組成物 |
JP2017203363A Active JP6509994B2 (ja) | 2006-03-14 | 2017-10-20 | ポビドンヨードを含む眼用組成物 |
JP2019006930A Active JP6817346B2 (ja) | 2006-03-14 | 2019-01-18 | ポビドンヨードを含む眼用組成物 |
JP2020126483A Withdrawn JP2020196718A (ja) | 2006-03-14 | 2020-07-27 | ポビドンヨードを含む眼用組成物 |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009500393A Active JP5415935B2 (ja) | 2006-03-14 | 2007-03-09 | ポビドンヨードを含む眼用組成物 |
JP2013034815A Active JP5709279B2 (ja) | 2006-03-14 | 2013-02-25 | ポビドンヨードを含む眼用組成物 |
JP2015021037A Active JP5997303B2 (ja) | 2006-03-14 | 2015-02-05 | ポビドンヨードを含む眼用組成物 |
JP2016134980A Active JP6389487B2 (ja) | 2006-03-14 | 2016-07-07 | ポビドンヨードを含む眼用組成物 |
JP2017203363A Active JP6509994B2 (ja) | 2006-03-14 | 2017-10-20 | ポビドンヨードを含む眼用組成物 |
JP2019006930A Active JP6817346B2 (ja) | 2006-03-14 | 2019-01-18 | ポビドンヨードを含む眼用組成物 |
Country Status (16)
Country | Link |
---|---|
US (8) | US7767217B2 (ja) |
EP (2) | EP1998783B1 (ja) |
JP (7) | JP5415935B2 (ja) |
KR (7) | KR102224121B1 (ja) |
CN (2) | CN103463635B (ja) |
AU (1) | AU2007225305B2 (ja) |
CA (2) | CA2645765C (ja) |
DK (1) | DK1998783T3 (ja) |
ES (2) | ES2488918T3 (ja) |
MX (3) | MX359415B (ja) |
NZ (5) | NZ734050A (ja) |
PL (1) | PL1998783T3 (ja) |
PT (1) | PT1998783E (ja) |
SI (1) | SI1998783T1 (ja) |
TW (4) | TWI677343B (ja) |
WO (1) | WO2007106381A2 (ja) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
EP2522343A1 (en) * | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
US20070232567A1 (en) * | 2006-03-28 | 2007-10-04 | Curtis Wright | Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin |
US8124130B1 (en) * | 2007-05-30 | 2012-02-28 | James Louis Rutkowski | Formulations and methods for recovery from dental surgery |
US20090263345A1 (en) * | 2008-01-28 | 2009-10-22 | Foresight Biotherapeutics, Inc. | Otic compositions for the treatment of infections of the internal and external ear in mammals |
WO2009097123A1 (en) * | 2008-01-28 | 2009-08-06 | Foresight Biotherapeutics, Inc. | Device for in-situ generation of povidone-iodine compositions |
JP2011512903A (ja) | 2008-02-25 | 2011-04-28 | アイゲート ファーマ エスエーエス | イオントフォレシスを介した眼組織への治療薬の向上した送達 |
AU2015252082B2 (en) * | 2008-06-12 | 2017-09-07 | Takeda Pharmaceutical Company Limited | Povidone iodine, a novel alternative preservative for ophthalmic compositions |
US20120027716A1 (en) * | 2008-06-12 | 2012-02-02 | Foresight Biotherapeutics, Inc. | Povidone Iodine, A Novel Alternative Preservative For Ophthalmic Compositions |
CN101987109B (zh) * | 2009-08-05 | 2012-07-04 | 天津金耀集团有限公司 | 含有聚维酮碘与环糊精包合糖皮质激素的眼用组合物 |
AU2015252097A1 (en) * | 2009-12-15 | 2015-11-19 | Foresight Biotherapeutics, Inc. | Non-irritating ophthalmic povidone-iodine compositions |
EP2512230A4 (en) * | 2009-12-15 | 2013-05-22 | Foresight Biotherapeutics Inc | NON-REFRACTORY OPHTHALMIC POVIDONE IOD COMPOSITIONS |
JP5699125B2 (ja) * | 2010-03-01 | 2015-04-08 | 株式会社オフテクス | コンタクトレンズ洗浄用水溶液及びそれを含むコンタクトレンズ洗浄用製剤セット |
MX2012011236A (es) * | 2010-03-30 | 2013-03-05 | Helperby Therapeutics Ltd | Combinacion y usos novedosos. |
KR101368587B1 (ko) | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
TWI717552B (zh) * | 2011-05-12 | 2021-02-01 | 美商遠景生物製藥股份有限公司 | 具有類固醇類或非類固醇抗發炎藥之安定的普維酮-碘(Povidone-Iodine)組合物 |
CN102448496B (zh) * | 2011-06-22 | 2015-04-15 | 江苏德达医药科技有限公司 | 含碘和类固醇的药物组合物及其用于治疗鼻炎疾病的用途 |
EP2559443A1 (en) | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
GB201114725D0 (en) | 2011-08-25 | 2011-10-12 | Altacor Ltd | Ophthalmic formulations |
CN102379893A (zh) * | 2011-08-29 | 2012-03-21 | 江苏德达医药科技有限公司 | 治疗皮炎的碘聚合物和糖皮质类固醇复方药物组合物 |
TW201808311A (zh) * | 2011-09-16 | 2018-03-16 | 遠景生物製藥股份有限公司 | 安定之普維酮-碘組成物 |
CN102429862B (zh) * | 2011-11-29 | 2013-05-01 | 江苏德达医药科技有限公司 | 一种聚维酮碘眼用缓释滴眼液 |
EP2797601B1 (en) * | 2012-02-10 | 2018-03-21 | Taiwan Liposome Company Ltd | Pharmaceutical compositions to reduce complications of ocular steroid |
US10485435B2 (en) | 2012-03-26 | 2019-11-26 | Medtronic, Inc. | Pass-through implantable medical device delivery catheter with removeable distal tip |
CN102988424A (zh) * | 2012-12-29 | 2013-03-27 | 潍坊富邦药业有限公司 | 一种加速动物伤口愈合、止痛生肌的喷雾剂及制备工艺 |
WO2015142853A1 (en) * | 2014-03-17 | 2015-09-24 | Encompass Development, Inc. | Ocular formulations |
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
WO2015198290A1 (es) * | 2014-06-27 | 2015-12-30 | Inversiones E Innovaciones Capel S.A.S. | Composiciones microbicidas incoloras que comprenden un yodóforo |
US11484580B2 (en) * | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
EP3247365A4 (en) | 2015-01-20 | 2018-08-01 | Veloce BioPharma LLC | Novel iodophor composition and methods of use |
JP2018513117A (ja) | 2015-03-05 | 2018-05-24 | オークランド ユニサービシズ リミテッドAuckland Uniservices Limited | 眼科用組成物およびその使用方法 |
KR20170141774A (ko) * | 2015-04-29 | 2017-12-26 | 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 | 항바이러스 및 항염증 치료제의 치료 조합물 |
CN107847432A (zh) | 2015-05-29 | 2018-03-27 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
JP6888754B2 (ja) | 2015-10-25 | 2021-06-16 | アイビュー セラピューティクス,インコーポレイテッド | インサイチュでゲルを形成する医薬製剤 |
US20180338911A1 (en) * | 2015-10-28 | 2018-11-29 | David B. Welch | Eye Drops |
ITUA20162425A1 (it) * | 2016-04-08 | 2017-10-08 | Medivis S R L | Composizione oftalmica che comprende PVP-I |
WO2017193060A1 (en) * | 2016-05-05 | 2017-11-09 | Veloce Biopharma, Llc | Compositions and methods for treatment of inflammation or infection of the eye |
US10925894B2 (en) | 2017-05-05 | 2021-02-23 | Gregory J. PAMEL | Composition containing chlorine dioxide and methods for using same |
KR101935250B1 (ko) * | 2017-07-04 | 2019-01-04 | 김대황 | 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물 |
WO2019009630A1 (ko) * | 2017-07-04 | 2019-01-10 | 김대황 | 수용해성이 향상된 요오드제 및 염화나트륨을 포함하는 고체 조성물 및 이의 수용액을 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물 |
CN107412215A (zh) * | 2017-08-15 | 2017-12-01 | 樊长春 | 一种滴眼剂及其制备方法 |
WO2019046844A1 (en) | 2017-09-02 | 2019-03-07 | Iview Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS FORMING IN SITU A GEL AND THEIR USES FOR SINUS DISEASES |
US20190209471A1 (en) * | 2018-01-11 | 2019-07-11 | Panaseea, LLC | Buffered compositions and methods for their use in surface treatments |
US10292998B1 (en) * | 2018-08-07 | 2019-05-21 | Ahad Mahootchi | Compositions and methods for prevention and treatment of eye infections |
KR20210137426A (ko) | 2019-03-12 | 2021-11-17 | 에이지씨 가부시키가이샤 | 액상 조성물, 파우더, 및, 파우더의 제조 방법 |
CA3171997A1 (en) * | 2020-03-16 | 2021-09-23 | Carl C. Awh | Ophthalmic compositions comprising a mixture of an antiseptic and an anesthetic |
US20230105599A1 (en) * | 2020-03-28 | 2023-04-06 | Iview Therapeutics, Inc. | Aqueous Formulations Containing Povidone Iodine for Effective Treatment and Prevention of Virus Infections |
NL2025640B1 (en) * | 2020-04-17 | 2023-05-15 | Veloce Biopharma Llc | Methods and composition for improved antisepsis |
CN116390993A (zh) | 2020-11-06 | 2023-07-04 | 大金工业株式会社 | 水性涂料组合物及涂装物品 |
JP7089210B2 (ja) | 2020-11-06 | 2022-06-22 | ダイキン工業株式会社 | 水性塗料組成物及び塗装物品 |
KR20220062790A (ko) | 2020-11-09 | 2022-05-17 | 정춘영 | 포비돈 아이오딘계 소독액 |
US12023344B2 (en) * | 2022-05-25 | 2024-07-02 | Famygen Life Sciences, Inc. | Topical otic, ophthalmic, and nasal corticosteroid formulations |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3584211A (en) | 1968-10-07 | 1971-06-08 | American Cyanamid Co | Chemiluminescent liquid dispensing or display container |
US3886268A (en) * | 1972-05-30 | 1975-05-27 | Synergistics | Iodophor-steroid compound pharmaceutical compositions |
US4177268A (en) | 1973-05-30 | 1979-12-04 | Jouveinal S.A. | Method of alleviating inflammation by administration of dexamethasone derivatives |
US4001388A (en) | 1973-06-14 | 1977-01-04 | Alza Corporation | Ophthalmological bioerodible drug dispensing formulation |
US4115544A (en) | 1976-08-18 | 1978-09-19 | Alza Corporation | Ocular system made of bioerodible esters having linear ether |
US4186184A (en) | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
CA1303503C (en) * | 1987-11-10 | 1992-06-16 | Marc Plamondon | Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex |
US5149694A (en) * | 1988-03-09 | 1992-09-22 | Alcon Laboratories, Inc. | Combination of tobramycin and dexamethasone for topical ophthalmic use |
EP0365613B1 (en) | 1988-03-09 | 1995-05-17 | Alcon Laboratories, Inc. | Combination of tobramycin and steroids for topical ophthalmic use |
US5149693A (en) | 1988-03-09 | 1992-09-22 | Alcon Laboratories, Inc. | Combination of tobramycin and fluorometholone for topical ophthalmic use |
US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US4865846A (en) | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
US5232692A (en) * | 1989-04-28 | 1993-08-03 | Research And Education Institute, Inc. | Povidone-iodine neonatal ophthalmic antimicrobial prophylactic agent |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
NL9002049A (nl) * | 1990-09-18 | 1992-04-16 | Dagra Pharma Bv | Oogheelkundig preparaat dat een povidon-joodoplossing bevat. |
US5126127A (en) * | 1991-07-16 | 1992-06-30 | Euroceltique, S.A. | Stabilized PVP-I solutions |
US5126177A (en) | 1991-10-28 | 1992-06-30 | Johnson Enterprises, Inc. | Thermoplastic preform for blow molding a bottle with reinforcing ribs |
US6328991B1 (en) | 1992-10-21 | 2001-12-11 | John Myhling | Composition and method for prevention of sexually transmitted diseases, including aids |
US5879717A (en) | 1993-02-10 | 1999-03-09 | Rita McConn-Stern | Wound healing compositions containing iodine and sucrose |
US5433714A (en) * | 1993-04-06 | 1995-07-18 | Bloomberg; Leroy | Topical anesthesia method for eye surgery, and applicator therefor |
US5490938A (en) | 1993-12-20 | 1996-02-13 | Biopolymerix, Inc. | Liquid dispenser for sterile solutions |
US5849291A (en) * | 1994-10-17 | 1998-12-15 | Symbollon Corporation | Opthalmic non-irritating iodine medicament |
DE19729879C2 (de) * | 1997-07-11 | 1999-07-08 | Mann Gerhard Chem Pharm Fab | Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin |
IL121647A (en) * | 1997-08-28 | 2001-07-24 | Pharmateam Dev Ltd | Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate |
CN1320880C (zh) | 1998-12-23 | 2007-06-13 | 伊迪亚股份公司 | 改进的体内局部无创伤用制剂 |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
US6036005A (en) | 1999-05-11 | 2000-03-14 | Krause; Arthur A. | Package for storing, mixing and dispensing multi-component products |
MXPA01012169A (es) | 1999-05-27 | 2002-06-21 | Euro Celtique Sa | Preparaciones para la aplicacion de agentes anti-infecciosos y/o anti-lamatorios para partes externas o internas del cuerpo humano o animal en la remodelacion funcional y cosmetica y tratamientos para reparacion de tejidos. |
US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
AR031135A1 (es) * | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
AR034371A1 (es) * | 2001-06-08 | 2004-02-18 | Novartis Ag | Composiciones farmaceuticas |
FR2826263B1 (fr) | 2001-06-26 | 2005-02-25 | Oreal | Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un compose anti-inflammatoire |
JP2006510657A (ja) | 2002-12-06 | 2006-03-30 | アライバ ファーマシューティカルズ,インコーポレイティド | 中耳炎の処置のための方法および組成物 |
US20070148192A1 (en) * | 2003-02-21 | 2007-06-28 | Laddha Ritu N | Stable ophthalmic composition |
US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
JP4893305B2 (ja) * | 2003-06-19 | 2012-03-07 | ボーダー、ニコラス・エス | 局所又は他の局部投与用のソフト抗炎症性ステロイドの活性及び/又は作用持続性の増強 |
US20050095205A1 (en) * | 2003-10-31 | 2005-05-05 | Ramesh Krishnamoorthy | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
GB2408937A (en) | 2003-12-09 | 2005-06-15 | Johnson & Johnson Medical Ltd | pH dependent medicinal compositions |
WO2005082380A1 (en) * | 2004-02-26 | 2005-09-09 | Advanced Ocular Systems Limited | Heparin for the treatment of ocular pathologies |
US20050191270A1 (en) | 2004-02-27 | 2005-09-01 | Hydromer, Inc. | Anti-infectious hydrogel compositions |
WO2005099715A2 (en) * | 2004-04-08 | 2005-10-27 | Retmed Pty Ltd. | Treatment of ophthalmic conditions with mineralcorticoids |
US20050255131A1 (en) | 2004-05-11 | 2005-11-17 | Mohan Vishnupad | Clindamycin compositions and delivery system therefor |
ATE439123T1 (de) | 2004-07-02 | 2009-08-15 | Novagali Pharma Sa | Verwendung von emulsionen zur intra- und periocularen injection |
CA2548532C (en) | 2004-09-27 | 2014-12-02 | Jan De Rijk | Methods and compositions for treatment of water |
US20060067978A1 (en) | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly(vinyl alcohol) drug delivery devices |
US20060068012A1 (en) | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control |
WO2006039558A2 (en) | 2004-10-09 | 2006-04-13 | Formurex, Inc. | Ocular agent delivery systems |
US8476319B2 (en) | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
US20060280809A1 (en) | 2005-06-14 | 2006-12-14 | Leshchiner Adele K | Anti-infective iodine based compositions for otic and nasal use |
US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
TWI394564B (zh) | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
CN1965857A (zh) | 2006-11-09 | 2007-05-23 | 武汉伊繁生物医药科技有限公司 | 聚维酮碘滴眼液及制备方法 |
US20080167281A1 (en) | 2007-01-05 | 2008-07-10 | Preston David M | Combination Otic Formulation |
US20080172032A1 (en) | 2007-01-11 | 2008-07-17 | James Pitzer Gills | Method for preventing tissue damage associated with irrigation of tissue with an antimicrobial solution |
WO2008137658A1 (en) | 2007-05-03 | 2008-11-13 | Mayo Foundation For Medical Education And Research | Otitis externa |
US20090263345A1 (en) | 2008-01-28 | 2009-10-22 | Foresight Biotherapeutics, Inc. | Otic compositions for the treatment of infections of the internal and external ear in mammals |
WO2009097123A1 (en) | 2008-01-28 | 2009-08-06 | Foresight Biotherapeutics, Inc. | Device for in-situ generation of povidone-iodine compositions |
EP2512230A4 (en) | 2009-12-15 | 2013-05-22 | Foresight Biotherapeutics Inc | NON-REFRACTORY OPHTHALMIC POVIDONE IOD COMPOSITIONS |
TWI717552B (zh) * | 2011-05-12 | 2021-02-01 | 美商遠景生物製藥股份有限公司 | 具有類固醇類或非類固醇抗發炎藥之安定的普維酮-碘(Povidone-Iodine)組合物 |
US9514501B2 (en) * | 2013-06-14 | 2016-12-06 | Tencent Technology (Shenzhen) Company Limited | Systems and methods for multimedia-processing |
-
2006
- 2006-12-07 US US11/636,293 patent/US7767217B2/en active Active
-
2007
- 2007-03-09 KR KR1020207014840A patent/KR102224121B1/ko active IP Right Grant
- 2007-03-09 NZ NZ734050A patent/NZ734050A/en unknown
- 2007-03-09 NZ NZ701559A patent/NZ701559A/en unknown
- 2007-03-09 MX MX2015015817A patent/MX359415B/es unknown
- 2007-03-09 CA CA2645765A patent/CA2645765C/en active Active
- 2007-03-09 MX MX2008011644A patent/MX2008011644A/es active IP Right Grant
- 2007-03-09 KR KR1020147013505A patent/KR101538280B1/ko active IP Right Grant
- 2007-03-09 AU AU2007225305A patent/AU2007225305B2/en active Active
- 2007-03-09 DK DK07752695.2T patent/DK1998783T3/da active
- 2007-03-09 MX MX2012006222A patent/MX336328B/es unknown
- 2007-03-09 WO PCT/US2007/006013 patent/WO2007106381A2/en active Application Filing
- 2007-03-09 KR KR1020197007751A patent/KR102116723B1/ko active IP Right Grant
- 2007-03-09 KR KR1020147029547A patent/KR20140130246A/ko not_active Application Discontinuation
- 2007-03-09 KR KR1020187003766A patent/KR20180016644A/ko not_active Application Discontinuation
- 2007-03-09 SI SI200731499T patent/SI1998783T1/sl unknown
- 2007-03-09 NZ NZ718955A patent/NZ718955A/en unknown
- 2007-03-09 ES ES07752695.2T patent/ES2488918T3/es active Active
- 2007-03-09 KR KR1020167028354A patent/KR102044600B1/ko active IP Right Grant
- 2007-03-09 CA CA2935366A patent/CA2935366A1/en not_active Abandoned
- 2007-03-09 PT PT77526952T patent/PT1998783E/pt unknown
- 2007-03-09 NZ NZ610068A patent/NZ610068A/en unknown
- 2007-03-09 CN CN201310305836.8A patent/CN103463635B/zh active Active
- 2007-03-09 ES ES14162854T patent/ES2807552T3/es active Active
- 2007-03-09 KR KR1020087025058A patent/KR101457710B1/ko active IP Right Grant
- 2007-03-09 EP EP07752695.2A patent/EP1998783B1/en active Active
- 2007-03-09 EP EP14162854.5A patent/EP2772258B1/en active Active
- 2007-03-09 NZ NZ571236A patent/NZ571236A/en not_active IP Right Cessation
- 2007-03-09 CN CN200780008873.5A patent/CN101400355B/zh active Active
- 2007-03-09 JP JP2009500393A patent/JP5415935B2/ja active Active
- 2007-03-09 PL PL07752695T patent/PL1998783T3/pl unknown
- 2007-03-13 TW TW106102178A patent/TWI677343B/zh active
- 2007-03-13 TW TW102106041A patent/TWI499422B/zh active
- 2007-03-13 TW TW096108626A patent/TWI395588B/zh active
- 2007-03-13 TW TW104119987A patent/TWI653978B/zh active
-
2010
- 2010-06-14 US US12/814,836 patent/US8562963B2/en active Active
- 2010-07-28 US US12/845,544 patent/US8394364B2/en active Active
-
2013
- 2013-02-25 JP JP2013034815A patent/JP5709279B2/ja active Active
- 2013-03-07 US US13/789,130 patent/US8765724B2/en active Active
-
2014
- 2014-06-26 US US14/316,300 patent/US9387223B2/en active Active
-
2015
- 2015-01-23 US US14/603,909 patent/US20150139932A1/en not_active Abandoned
- 2015-02-05 JP JP2015021037A patent/JP5997303B2/ja active Active
- 2015-10-27 US US14/923,845 patent/US9855295B2/en active Active
-
2016
- 2016-07-07 JP JP2016134980A patent/JP6389487B2/ja active Active
-
2017
- 2017-10-20 JP JP2017203363A patent/JP6509994B2/ja active Active
- 2017-11-28 US US15/823,996 patent/US10849928B2/en active Active
-
2019
- 2019-01-18 JP JP2019006930A patent/JP6817346B2/ja active Active
-
2020
- 2020-07-27 JP JP2020126483A patent/JP2020196718A/ja not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020196718A5 (ja) | ||
US10849928B2 (en) | Methods of using ophthalmic compositions comprising povidone-iodine | |
AU2012308424B2 (en) | Stable povidone-iodine compositions | |
JP2014516954A5 (ja) | ||
AU2016253668B2 (en) | Ophthalmic compositions comprising povidone-iodine | |
AU2013203462B2 (en) | Ophthalmic compositions comprising povidone-iodine |